IP Library Granted Patent US 9,295,727
Granted Patent B2
US 9,295,727 · App. 14/182,557 · Granted Mar 29, 2016

Cancer cell targeting using nanoparticles

Inventors: Stephen E. Zale (Hopkinton, MA); Mir Mukkaram Ali (Woburn, MA)
Assignee: BIND Therapeutics, Inc.
A61K47/34A61K9/0002A61K9/146A61K9/5153A61K9/5192A61K31/197A61K31/337A61K47/48038A61K47/48907A61K47/48915B82Y5/00C07C275/16C07C275/24C08G63/664C08G63/6852C08G63/6922Y10S977/904Y10S977/905Y10S977/906Y10S977/911Y10S977/915
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,295,727
App. No.
14/182,557
Granted
Mar 29, 2016
Kind
B2
Abstract

The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Claims (16)

1. A pharmaceutical composition comprising:

a pharmaceutically acceptable carrier; and

a plurality of nanoparticles, wherein the nanoparticles each comprise:

a chemotherapeutic agent;

a diblock copolymer of poly (ethylene)glycol and polylactic acid; and

a ligand conjugate represented by:

wherein:

R 1 and R 3 are alkyl groups;

R 2 is an ester or amide linkage;

X/(X+Y) is 0.5 to 1;

Y/(X+Y) is 0 to 0.5;

X+Y is 20 to 1720; and

Z is 25 to 455.

2. The pharmaceutical composition of claim 1 , wherein Y is 0.

3. The pharmaceutical composition of claim 2 , wherein R 2 is an ester linkage.

4. The pharmaceutical composition of claim 1 , wherein the chemotherapeutic agent is docetaxel.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2017
From: BIND THERAPEUTICS, INC.
To: PFIZER INC.
Reel/Frame 041184/0022 →
Continuity (5)
Continuation 13595592 · Aug 27, 2012
Continuation 13109425 · May 17, 2011
Continuation 12059496 · Mar 31, 2008
Provisional Application 60976197 · Sep 28, 2007
Related Publication 20140235706A1 · Aug 21, 2014